Understanding atrial fibrillation and new therapeutic advances to improve its management

May 2010
American Journal of Health-System Pharmacy;5/2/2010 Supplement, pS35
Academic Journal
The article presents several questions for the readers related to atrial fibrillation as discussed in the journal. It states a question about the prevalence, pathophysiology, and consequences of atrial fibrillation. It also states a question on the dissimilarities between pharmacology, efficacy, and anticoagulant medications. It also mentions several questions with multiple choice options.


Related Articles

  • Review : In AF with CKD, novel oral anticoagulants reduce stroke or systemic embolism compared with warfarin. DeLoughery, Thomas // Annals of Internal Medicine;11/18/2014, Vol. 161 Issue 10, pJC4 

    The article focuses on a study on the effectiveness of anticoagulation therapy in reducing risk for thromboembolism in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). It mentions that the novel oral anticoagulants (NOACs) reduce stroke or systemic embolism compared with...

  • Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer? Wolfram, Oliver; Hammwoehner, Matthias; Gramley, Felix; Goette, Andreas // Current Vascular Pharmacology;May2011, Vol. 9 Issue 3, p350 

    No abstract available.

  • Should Atrial Fibrillation Burden Be A Feature to Guide Thromboembolism Prophylaxis? Sachdev, Molly; Daoud, Emile G. // JAFIB: Journal of Atrial Fibrillation;Aug2012, Vol. 5 Issue 2, p18 

    Atrial fibrillation (AF) is a well-known risk factor for cerebrovascular events and systemic emboli. However, the frequency and duration of AF necessary to be considered at risk for thrombus formation is unknown. This review summarizes the literature regarding AF burden and risk for...

  • Management of atrial fibrillation. Lafuente-Lafuente, Carmelo; Mahé, Isabelle; Extramiana, Fabrice // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/2/2010, Vol. 340 Issue 7736, p40 

    The article discusses the diagnosis, treatment and management of atrial fibrillation (AF). Public health burden associated with AF is reportedly increasing as its prevalence also increases with age. Clinical manifestations of the disease include a chaotic electrical activity in the atria and a...

  • Dabigatran: Will It Replace Warfarin for Stroke Prevention in Atrial Fibrillation? Howard, Patricia A. // Hospital Pharmacy;Mar2012, Vol. 47 Issue 3, p181 

    The article offers information on thrombin inhibitor Dabigatran, a warfarin oral alternative to prevent stroke in atrial fibrillation (AT). It states that the U.S. Food and Drug Administration (FDA) approved the 150 milligram (mg) dose of dabigatran for stroke prevention after it was compared...

  • Triple therapy (aspirin, Clopidogrel and oral anticoagulant) after percutaneous coronary intervention: another call for personalized medicine. Tanrıkulu, Azra; Ağırbaşlı, Mehmet // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Aug2013, Vol. 13 Issue 5, p486 

    Studies indicate that 5-7% patients undergoing percutaneous coronary intervention (PCI) have an indication for anticoagulation therapy. Most commonly atrial fibrillation (AF) is the indication. These subjects require triple therapy with aspirin, Clopidogrel, and an oral antico-agulant (OAC)....

  • ARISTOTLE trial finds new drug may revolutionize the treatment of atrial fibrillation.  // Biomedical Market Newsletter;10/31/2011, Vol. 21, p1301 

    The article reports on a study by the Heart and Stroke Foundation of Canada which finds the potential of a new drug to revolutionize the treatment of atrial fibrillation (AF). Justin Ezekowitz of the University of Alberta has said that majority of AF patients need an anticoagulant which can have...

  • Consistency of Safety and Efficacy of New Oral Anticoagulants across Subgroups of Patients with Atrial Fibrillation. Lega, Jean-Christophe; Bertoletti, Laurent; Gremillet, Cyrielle; Chapelle, Céline; Mismetti, Patrick; Cucherat, Michel; Vital-Durand, Denis; Laporte, Silvy // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Aims: The well-known limitations of vitamin K antagonists (VKA) led to development of new oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta-analysis was to determine the consistency of treatment effects of NOAC irrespective of age, comorbidities, or...

  • Heart Failure.  // Diseases & Disorders: A Nursing Therapeutics Manual, 2nd edition;2002, p417 

    Provides information on heart failure, a condition that occurs when the heart is unable to pump sufficient blood to meet the metabolic needs of the body. Physiological manifestations of the condition; Causes of heart failure; Clinical diagnosis and management of the condition.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics